Lightning Flash™ is the most advanced mechanical thrombectomy system on the market to address venous and pulmonary thrombus Next generation technology combines superior catheter design with the latest ...

Penumbra ($PEN), one of the top devicemaker IPOs last year, unveiled its latest thrombectomy product to the U.S. market. Dubbed the ACE 68 Reperfusion Catheter, the ...

Penumbra, Inc. (NYSE:PEN), a leader in the medical technology sector specializing in thrombectomy devices, has been garnering attention from analysts due to its strong performance and promising ...

The COMPASS Trial results were featured in the main event plenary session at the International Stroke Conference and add to the growing body of evidence demonstrating Penumbra’s aspiration system is ...

Adam Elsesser, Chairman and CEO, highlighted that Penumbra achieved total revenue of $324.1 million in Q1 2025, representing year-over-year growth of 16.3% on a reported basis and 16.9% in constant ...

Latest STRIKE-PE data show that computer assisted vacuum thrombectomy (CAVT) for the treatment of pulmonary embolism is safe and effective at reducing right heart strain; it also improved clinical and ...

Penumbra, Inc. (NYSE:PEN) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds. The company announced the completion of enrollment in STORM-PE clinical trial. The pivotal, ...

Penumbra, Inc. PEN recently received FDA clearance for the RED 62 Reperfusion Catheter. Following this regulatory go-ahead, the company has also initiated commercial availability of the catheter ...

ALAMEDA, Calif.--(BUSINESS WIRE)--Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced U.S. commercial availability of the Penumbra System’s most ...

Penumbra, Inc., a global healthcare company focused on innovative therapies, today announced U.S. commercial availability of the Penumbra System's most advanced technology: Penumbra JET 7 and Penumbra ...